A detailed history of Goldman Sachs Group Inc transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 144,307 shares of RPHM stock, worth $242,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144,307
Previous 38,751 272.4%
Holding current value
$242,435
Previous $64,000 239.06%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.51 - $1.9 $159,389 - $200,556
105,556 Added 272.4%
144,307 $217,000
Q1 2024

May 15, 2024

SELL
$1.59 - $1.74 $41,395 - $45,300
-26,035 Reduced 40.19%
38,751 $64,000
Q4 2023

Feb 13, 2024

BUY
$1.34 - $8.43 $30,116 - $189,464
22,475 Added 53.12%
64,786 $103,000
Q3 2023

May 14, 2024

SELL
$5.44 - $8.13 $122,264 - $182,721
-22,475 Reduced 34.69%
42,311 $322,000
Q3 2023

Nov 14, 2023

BUY
$5.44 - $8.13 $230,171 - $343,988
42,311 New
42,311 $322,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.